About mosunetuzumab
CD20×CD3 bispecific antibody
Used for
- Treatment of adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies.
Usual adult dose
Intravenous infusion in 21-day cycles: 1 mg on day 1, 2 mg on day 8, 60 mg on day 15 of cycle 1; then 60 mg on day 1 of cycle 2; then 30 mg on day 1 of later cycles, usually for up to 8 cycles.
Common side effects
- Cytokine release syndrome
- Low blood-cell counts
- Fatigue
- Infections
Important warnings
- Cytokine release syndrome can be severe or life-threatening, especially during early doses.
- Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, can occur.
- Serious infections and prolonged low blood-cell counts may occur.
- Treatment requires monitoring and supportive care by clinicians experienced with these toxicities.
Pregnancy
May harm an unborn baby. Pregnancy status should be checked before treatment; effective contraception is advised during treatment and for 3 months afterward.
Breastfeeding
Avoid breastfeeding during treatment and for 3 months after the last dose.
Interactions
- No specific drug interactions are well established; tell clinicians about all medicines, including vaccines.
- Avoid live vaccines during treatment and until immune recovery.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.